342 related articles for article (PubMed ID: 32992231)
1. Cancer genomics of lung cancer including malignant mesothelioma: A brief overview of current status and future prospects.
Jhanwar SC; Xu XL; Elahi AH; Abramson DH
Adv Biol Regul; 2020 Dec; 78():100723. PubMed ID: 32992231
[TBL] [Abstract][Full Text] [Related]
2. [Driver genes expression and clinical characteristics of targeted therapy in non-small cell lung cancer in Yunnan-Kweichow Plateau].
Lin YP; Li Q; Ma LY; Liu X; Dai M; Wang XX; Li HS; Liu JX; Shen ZH; Guo YJ; Du YX; Yang RJ; Huang YC; Zhou YC
Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):735-740. PubMed ID: 32988155
[No Abstract] [Full Text] [Related]
3. Molecular genetics of small cell lung carcinoma.
Wistuba II; Gazdar AF; Minna JD
Semin Oncol; 2001 Apr; 28(2 Suppl 4):3-13. PubMed ID: 11479891
[TBL] [Abstract][Full Text] [Related]
4. Mutational Profiling of Driver Tumor Suppressor and Oncogenic Genes in Brazilian Malignant Pleural Mesotheliomas.
Campanella NC; Silva EC; Dix G; de Lima Vazquez F; Escremim de Paula F; Berardinelli GN; Balancin M; Chammas R; Mendoza Lopez RV; Silveira HCS; Capelozzi VL; Reis RM
Pathobiology; 2020; 87(3):208-216. PubMed ID: 32369821
[TBL] [Abstract][Full Text] [Related]
5. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
Shea M; Costa DB; Rangachari D
Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
[TBL] [Abstract][Full Text] [Related]
6. Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma.
Andujar P; Pairon JC; Renier A; Descatha A; Hysi I; Abd-Alsamad I; Billon-Galland MA; Blons H; Clin B; Danel C; Debrosse D; Galateau-Sallé F; Housset B; Laurent-Puig P; Le Pimpec-Barthes F; Letourneux M; Monnet I; Régnard JF; Validire P; Zucman-Rossi J; Jaurand MC; Jean D
Mutagenesis; 2013 May; 28(3):323-31. PubMed ID: 23435014
[TBL] [Abstract][Full Text] [Related]
7. Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.
Modi S; Kubo A; Oie H; Coxon AB; Rehmatulla A; Kaye FJ
Oncogene; 2000 Sep; 19(40):4632-9. PubMed ID: 11030152
[TBL] [Abstract][Full Text] [Related]
8. [News about targeted therapies in non-small-cell lung cancer in 2015 (except immuno-therapy)].
Hamard C; Ruppert AM; Lavole A; Rozensztajn N; Antoine M; Cadranel J; Wislez M
Ann Pathol; 2016 Jan; 36(1):63-72. PubMed ID: 26775573
[TBL] [Abstract][Full Text] [Related]
9. A personalized treatment for lung cancer: molecular pathways, targeted therapies, and genomic characterization.
Hensing T; Chawla A; Batra R; Salgia R
Adv Exp Med Biol; 2014; 799():85-117. PubMed ID: 24292963
[TBL] [Abstract][Full Text] [Related]
10. Genomic characterization and detection of potential therapeutic targets for peritoneal mesothelioma in current practice.
van Kooten JP; Dietz MV; Dubbink HJ; Verhoef C; Aerts JGJV; Madsen EVE; von der Thüsen JH
Clin Exp Med; 2024 Apr; 24(1):80. PubMed ID: 38642130
[TBL] [Abstract][Full Text] [Related]
11. Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches.
Drilon A; Wang L; Arcila ME; Balasubramanian S; Greenbowe JR; Ross JS; Stephens P; Lipson D; Miller VA; Kris MG; Ladanyi M; Rizvi NA
Clin Cancer Res; 2015 Aug; 21(16):3631-9. PubMed ID: 25567908
[TBL] [Abstract][Full Text] [Related]
12. Genetic and epigenetic pathways in myelodysplastic syndromes: A brief overview.
Jhanwar SC
Adv Biol Regul; 2015 May; 58():28-37. PubMed ID: 25499150
[TBL] [Abstract][Full Text] [Related]
13. Pathways Impacted by Genomic Alterations in Pulmonary Carcinoid Tumors.
Asiedu MK; Thomas CF; Dong J; Schulte SC; Khadka P; Sun Z; Kosari F; Jen J; Molina J; Vasmatzis G; Kuang R; Aubry MC; Yang P; Wigle DA
Clin Cancer Res; 2018 Apr; 24(7):1691-1704. PubMed ID: 29351916
[No Abstract] [Full Text] [Related]
14. Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer.
Lin MW; Su KY; Su TJ; Chang CC; Lin JW; Lee YH; Yu SL; Chen JS; Hsieh MS
Lung Cancer; 2018 Nov; 125():282-290. PubMed ID: 30429033
[TBL] [Abstract][Full Text] [Related]
15. Genomic Landscape of Malignant Mesotheliomas.
Kato S; Tomson BN; Buys TP; Elkin SK; Carter JL; Kurzrock R
Mol Cancer Ther; 2016 Oct; 15(10):2498-2507. PubMed ID: 27507853
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers for personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
[TBL] [Abstract][Full Text] [Related]
17. Lung cancer mutation profile of EGFR, ALK, and KRAS: Meta-analysis and comparison of never and ever smokers.
Chapman AM; Sun KY; Ruestow P; Cowan DM; Madl AK
Lung Cancer; 2016 Dec; 102():122-134. PubMed ID: 27987580
[TBL] [Abstract][Full Text] [Related]
18. Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative.
Lim SM; Kim EY; Kim HR; Ali SM; Greenbowe JR; Shim HS; Chang H; Lim S; Paik S; Cho BC
Oncotarget; 2016 Apr; 7(17):24172-8. PubMed ID: 26992220
[TBL] [Abstract][Full Text] [Related]
19. Genes associated with increased brain metastasis risk in non-small cell lung cancer: Comprehensive genomic profiling of 61 resected brain metastases versus primary non-small cell lung cancer (Guangdong Association Study of Thoracic Oncology 1036).
Wang H; Ou Q; Li D; Qin T; Bao H; Hou X; Wang K; Wang F; Deng Q; Liang J; Zheng W; Wu X; Wang X; Shao YW; Mou Y; Chen L
Cancer; 2019 Oct; 125(20):3535-3544. PubMed ID: 31287555
[TBL] [Abstract][Full Text] [Related]
20.
Chung WJ; Daemen A; Cheng JH; Long JE; Cooper JE; Wang BE; Tran C; Singh M; Gnad F; Modrusan Z; Foreman O; Junttila MR
Proc Natl Acad Sci U S A; 2017 Dec; 114(51):E10947-E10955. PubMed ID: 29203670
[No Abstract] [Full Text] [Related]
[Next] [New Search]
